Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is a promising biopharmaceutical company in the genetic medicine space with a focus on RNA editing technology. Their lead program, KRRO-121, is designed to address hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. The company has a strong pipeline of programs and is well-funded, with a positive outlook for their upcoming AATD development candidate nomination in 2Q26. Key highlights include high-potency RNA editing, strong pre-clinical and NHP data, and a clear regulatory path established for their target indications. With a differentiated approach, strong potential market opportunity, and a solid financial standing, Korro Bio has a clear value proposition for investors looking for potential blockbuster opportunities and a risk-mitigated setup ahead of regulatory and clinical updates.

Bears say

Korro Bio is relying on a single lead asset, KRRO-121, to generate a stable variant of the enzyme glutamine synthase (GS) in order to address all patients with urea cycle disorder (UCD) and hepatic encephalopathy (HE), showcasing a limited pipeline and potential long-term success of the company. Furthermore, Korro Bio's lead asset is still in Phase 1 development and previous trials of RAVICTI, a similar treatment for UCD, have shown limited efficacy in reducing ammonia levels and rely solely on safety/tolerability as primary endpoints, indicating a lack of confidence in the drug's potential success. Finally, the company's sole source of revenue will be from this single asset, further highlighting the risk and limited potential returns for investors.

KRRO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 9 analysts, KRRO has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.